 |
34 Diseases |  |
0 Trials |
|
0 Trials |  |
33 News |  |
- | ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion date: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Feb 28, 2020
P=N/A, N=48, Completed, Sponsor: Bayer
Trial completion date: Dec 2018 --> Jun 2019
- azacitidine / Generic mfg.
Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia (Sunburst Room (W340) (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1418;
Consistent with our isogenic model data, we characterise biallelic somatic TET2 mutation in a patient with AML that was chemoresistant to anthracycline/cytarabine-based chemotherapy but acutely sensitive to 5-azacitidine, resulting in durable cytomorphological remission...In contrast, only 1 case with a TET2 mutation had a translocation affecting chromosome 4. In summary, our data argue in favour of using 5-azacitidine in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of personalised medicine for cancer patients.
- ||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=48, Completed, Sponsor: Bayer
In summary, our data argue in favour of using 5-azacitidine in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of personalised medicine for cancer patients. Recruiting --> Completed
- || ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion date, Trial primary completion date: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - May 3, 2018
P=N/A, N=45, Recruiting, Sponsor: Bayer
Recruiting --> Completed Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018
- || ciprofloxacin (Q3939) / Bayer, Novartis
Phase classification: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Apr 3, 2018
P, N=45, Recruiting, Sponsor: Bayer
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018 Phase classification: P=N/A --> P
- ciprofloxacin (Q3939) / Bayer, Novartis
Trial primary completion date: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=45, Recruiting, Sponsor: Bayer
Phase classification: P=N/A --> P Trial primary completion date: Sep 2017 --> Sep 2018
- ||||||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion: RESPIRE 2: Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Nov 25, 2016
P3, N=519, Completed, Sponsor: Bayer
Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment open: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Jul 20, 2016
P=N/A, N=45, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion, Enrollment change: Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo (clinicaltrials.gov) - Mar 30, 2016
P=N/A, N=46, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Completed | N=30 --> 46
- ||||||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Mar 17, 2016
P3, N=414, Completed, Sponsor: Bayer
Recruiting --> Completed | N=30 --> 46 Active, not recruiting --> Completed
- ciprofloxacin (Q3939) / Bayer, Novartis
New trial: Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=30, Recruiting, Sponsor: Bayer
- ciprofloxacin (Q3939) / Bayer, Novartis
Trial initiation date: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=45, Not yet recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Initiation date: Nov 2015 --> Feb 2016
- ||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment closed: RESPIRE 2: Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Nov 24, 2015
P3, N=473, Active, not recruiting, Sponsor: Bayer
Initiation date: Nov 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- ciprofloxacin (Q3939) / Bayer, Novartis
Trial primary completion date: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=45, Not yet recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Sep 2017
- ciprofloxacin (Q3939) / Bayer, Novartis
New trial: Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - Sep 21, 2015
P=N/A, N=45, Not yet recruiting, Sponsor: Bayer
- ||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment change, Trial primary completion date: RESPIRE 2: Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Jul 17, 2015
P3, N=450, Recruiting, Sponsor: Bayer
Trial primary completion date: Sep 2018 --> Sep 2017 N=300 --> 450 | Trial primary completion date: Aug 2016 --> Dec 2016
- ||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment closed: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 19, 2015
P3, N=414, Active, not recruiting, Sponsor: Bayer
N=300 --> 450 | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- || ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion: A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia (clinicaltrials.gov) - Apr 27, 2015
P3, N=44, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Completed
- | ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment change: A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia (clinicaltrials.gov) - Sep 19, 2014
P3, N=46, Recruiting, Sponsor: Bayer
Recruiting --> Completed N=30 --> 46
- ||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment change: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Aug 11, 2014
P3, N=400, Recruiting, Sponsor: Bayer
N=30 --> 46 N=300 --> 400
- |||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial primary completion date: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 7, 2014
P3, N=300, Recruiting, Sponsor: Bayer
N=300 --> 400 Trial primary completion date: Sep 2015 --> Mar 2016
- ||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion date: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 7, 2014
P3, N=300, Recruiting, Sponsor: Bayer
Trial primary completion date: Sep 2015 --> Mar 2016 Trial completion date: Oct 2015 --> Apr 2016
- |||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment open: RESPIRE 2: Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 5, 2014
P3, N=300, Recruiting, Sponsor: Bayer
Trial completion date: Oct 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- |||||||||| ciprofloxacin (Q3939) / Bayer, Novartis
New P3 trial: RESPIRE 2: Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Apr 6, 2014
P3, N=300, Not yet recruiting, Sponsor: Bayer
- ||||| ciprofloxacin (Q3939) / Bayer, Novartis
Trial initiation date: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 23, 2013
P3, N=300, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Jan 2013 --> May 2013
- |||||| ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment open: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - May 23, 2013
P3, N=300, Recruiting, Sponsor: Bayer
Initiation date: Jan 2013 --> May 2013 Not yet recruiting --> Recruiting
- |||||||||| ciprofloxacin (Q3939) / Bayer, Novartis
New P3 trial: RESPIRE 1: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (clinicaltrials.gov) - Jan 8, 2013
P3, N=300, Recruiting, Sponsor: Bayer
- ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment change: Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases (clinicaltrials.gov) - Aug 27, 2012
P1, N=24, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting N=19 --> 24
- ||| ciprofloxacin (Q3939) / Bayer, Novartis
Clinical: Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance (clinicaltrials.gov) - Aug 20, 2012
P=N/A, N=3274, Completed, Sponsor: Bayer
- | ciprofloxacin (Q3939) / Bayer, Novartis
Trial completion: Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases (clinicaltrials.gov) - Jul 2, 2012
P1, N=24, Completed, Sponsor: Bayer
N=19 --> 24 Recruiting --> Completed
- | ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment open: A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia (clinicaltrials.gov) - May 17, 2012
P3, N=30, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| ciprofloxacin (Q3939) / Bayer, Novartis
New P3 trial: A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia (clinicaltrials.gov) - Mar 21, 2012
P3, N=30, Recruiting, Sponsor: Bayer
- | ciprofloxacin (Q3939) / Bayer, Novartis
New P1 trial: Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases (clinicaltrials.gov) - Feb 22, 2012
P1, N=24, Completed, Sponsor: Bayer